Introduction
The breast cancer pipeline contains 156 drugs, the majority of which (68%) are targeted therapies. VEGFR remain the leading target for drug developers, but there are a number of innovative early stage approaches targeting the key signaling pathways in cancer cells. As new targeted therapies are developed physicians will need to establish the optimal combinations of these drugs.
Features and benefits
* In-depth analysis of breast cancer pipeline – development stage, therapeutic class, molecular targets, and changes in pipeline since 2006
* In-depth analysis of current comparator therapy – target product profile, unmet needs, and innovative early-stage approaches
* In-depth analysis of clinical trial design – patient selection, duration, clinical endpoints, and future developments in trial design
* The future of breast cancer treatment – increasing use of biomarkers, new combination therapies and novel targeted therapies
Highlights
A high unmet need remains for treatments that can provide durable clinical responses and improve quality of life. With the emergence of new technologies and the increased understanding of the pathogenesis of cancer, the molecular changes that distinguish malignant cells from normal cells are becoming increasingly apparent.
Drug developers are focusing on new targets to increase efficacy, reduce toxicity, and avoid strong competition. There are a number of innovative early stage approaches targeting the key signaling pathways in cancer cells. These include PI3K inhibitors, IGFR inhibitors, and CDK inhibitors.
Future breast cancer treatment will rely on new combination regimens, identification of new molecular targets, and increased use of biomarkers. The oncology market is undoubtedly moving towards personalized therapy and the breast cancer market is no exception.
Your key questions answered
* Identify key trends in the breast cancer pipeline, including development stage, molecular targets, and therapeutic class
* Identify the target product profile for new breast cancer therapies and innovative early-stage drug targets
* Assess key decisions in breast cancer clinical trial design regarding patient selection, trial duration, endpoints, and predictive biomarkers
[Studien Infos ausblenden]
